An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

The Food and Drug Administration refused to review Moderna’s application for its new mRNA flu vaccine — a move the pharma giant’s’s president Dr. Stephen Hoge said left him in “complete shock.” In an ...

The U.S. Food and Drug Administration (FDA) has refused to consider Moderna’s application for a new flu vaccine, which utilizes Nobel Prize-winning mRNA technology, the company announced on Tuesday.

In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls Commercial/Moment via Getty Images Ana Santos Rutschman, Villanova University ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...

The FDA has agreed to review Moderna’s investigational flu vaccine for potential approval, about a week after telling the drugmaker it would not consider the application. On Feb. 10, the agency ...

In December 2025, Moderna submitted an application to the FDA to approve an mRNA flu vaccine for adults age 50 and older. The vaccine had been tested in clinical trials including more than 40,000 ...

Moderna said today the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling drugmaker ...